About EPIGENETIX, INC.
Epigenetix is a biotechnology company focused on developing EP31670 (NEO2734), a first-in-class dual BRD4 and p300/CBP inhibitor for the treatment of various cancers, including myelofibrosis, metastatic castrate-resistant prostate cancer, NUT midline carcinoma, pancreatic cancer, and breast cancer. Clinical trials are ongoing at multiple leading cancer centers.
Development of first-in-class dual BRD4 and p300/CBP inhibitorsConducting clinical trials for multiple cancer indicationsPreclinical research and drug testing using 3D ex vivo modelsCollaboration with leading cancer research institutions
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to EPIGENETIX, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.